Surrozen Announces First Patient Dosed In Phase 1b Trial Of SZN-043 For Severe Alcohol-Associated Hepatitis
Portfolio Pulse from Benzinga Newsdesk
Surrozen has announced that the first patient has been dosed in its Phase 1b trial of SZN-043, a treatment for severe alcohol-associated hepatitis.
June 04, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Surrozen has dosed the first patient in its Phase 1b trial of SZN-043, targeting severe alcohol-associated hepatitis. This milestone could indicate progress in their clinical development pipeline.
Dosing the first patient in a Phase 1b trial is a significant milestone for Surrozen, indicating progress in their clinical development. This could positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100